142 related articles for article (PubMed ID: 33957960)
41. Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Bryk AH; Siudut J; Broniatowska E; Bagoly Z; Baráth B; Katona É; Undas A
Thromb Res; 2020 Jan; 185():55-62. PubMed ID: 31770688
[TBL] [Abstract][Full Text] [Related]
42. [Blind spots of the diagnostic hemostasis screen].
Levi M; Peters M; Briët E
Ned Tijdschr Geneeskd; 2000 Mar; 144(10):457-60. PubMed ID: 10726152
[TBL] [Abstract][Full Text] [Related]
43. The kidney is a major site of alpha(2)-antiplasmin production.
Menoud PA; Sappino N; Boudal-Khoshbeen M; Vassalli JD; Sappino AP
J Clin Invest; 1996 Jun; 97(11):2478-84. PubMed ID: 8647939
[TBL] [Abstract][Full Text] [Related]
44. [Parameters related to fibrinolysis and their meanings].
Urano T; Suzuki Y
Rinsho Byori; 2011 Jul; 59(7):703-8. PubMed ID: 21874797
[TBL] [Abstract][Full Text] [Related]
45. Coagulation and fibrinolysis.
Nilsson IM
Scand J Gastroenterol Suppl; 1987; 137():11-8. PubMed ID: 3321400
[TBL] [Abstract][Full Text] [Related]
46. Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.
Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
BMC Biotechnol; 2009 Mar; 9():15. PubMed ID: 19257897
[TBL] [Abstract][Full Text] [Related]
47. Impaired activation of the fibrinolytic system in children with Henoch-Schönlein purpura: beneficial effect of hydrocortisone plus Sigma-aminocaproic acid therapy on disappearance rate of cutaneous vasculitis and fibrinolysis.
Prandota J; Pankow-Prandota L; Kotecki L
Am J Ther; 2001; 8(1):11-9. PubMed ID: 11304653
[TBL] [Abstract][Full Text] [Related]
48. A bleeding disorder due to deficiency of alpha 2-antiplasmin.
Kettle P; Mayne EE
J Clin Pathol; 1985 Apr; 38(4):428-9. PubMed ID: 3988955
[TBL] [Abstract][Full Text] [Related]
49. 28-day thawed plasma maintains α
Stettler GR; Moore EE; Huebner BR; Nunns GR; Moore HB; Coleman JR; Kelher M; Banerjee A; Silliman CC
Vox Sang; 2021 Feb; 116(2):181-189. PubMed ID: 32894784
[TBL] [Abstract][Full Text] [Related]
50. Alpha 2-antiplasmin: functional characterization and metabolism in a heterozygote deficient patient.
Knot EA; ten Cate JW; Lamping RJ; Gie LK
Thromb Haemost; 1986 Jun; 55(3):375-8. PubMed ID: 3750266
[TBL] [Abstract][Full Text] [Related]
51. Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders.
Williams EC
Arch Intern Med; 1989 Aug; 149(8):1769-72. PubMed ID: 2475079
[TBL] [Abstract][Full Text] [Related]
52. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme.
Urano T; Ihara H; Takada Y; Fujie M; Takada A
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):145-53. PubMed ID: 10759007
[TBL] [Abstract][Full Text] [Related]
53. Implications of excessive fibrinolysis and alpha(2)-plasmin inhibitor deficiency in patients with severe head injury.
Kushimoto S; Yamamoto Y; Shibata Y; Sato H; Koido Y
Neurosurgery; 2001 Nov; 49(5):1084-9; discussion 1089-90. PubMed ID: 11846901
[TBL] [Abstract][Full Text] [Related]
54. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders.
Nogami K; Matsumoto T; Sasai K; Ogiwara K; Arai N; Shima M
Br J Haematol; 2019 Nov; 187(4):518-529. PubMed ID: 31335970
[TBL] [Abstract][Full Text] [Related]
55. A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency.
Hanss MM; Farcis M; Ffrench PO; de Mazancourt P; Dechavanne M
Blood Coagul Fibrinolysis; 2003 Jan; 14(1):107-11. PubMed ID: 12544738
[TBL] [Abstract][Full Text] [Related]
56. Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice.
Takei M; Matsuno H; Okada K; Ueshima S; Matsuo O; Kozawa O
J Thromb Thrombolysis; 2002 Dec; 14(3):205-11. PubMed ID: 12913400
[TBL] [Abstract][Full Text] [Related]
57. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
58. Hemorrhagic disorders of fibrinolysis: a clinical review.
Saes JL; Schols SEM; van Heerde WL; Nijziel MR
J Thromb Haemost; 2018 May; ():. PubMed ID: 29847021
[TBL] [Abstract][Full Text] [Related]
59. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Schleef RR; Higgins DL; Pillemer E; Levitt LJ
J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
[TBL] [Abstract][Full Text] [Related]
60. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
